Market Place
Sourcing Support
Novo Expands Pivotal Program After Amycretin Shines in Diabetes
25 Nov 2025 //
GLOBENEWSWIRE
Lilly’s Amylin Agonist Headed to Ph3 After upto 20% Weight Loss
08 Nov 2025 //
PR NEWSWIRE
Novo`s CEO Doesn`T Seem To Mind Being Big Pharma`s Villian
31 Oct 2025 //
BIOSPACE
Ascletis Chooses ASC36, A Monthly Subcutaneous Amylin Agonist
30 Oct 2025 //
PR NEWSWIRE
Novo`s Amylin Injectable Cagrilintide Achieves 11.8% Weight Loss
16 Sep 2025 //
BIOSPACE
Novo Nordisk Unveils Phase 3 Data for Amylin Cagrilintide
16 Sep 2025 //
GLOBENEWSWIRE
Novo Nordisk Reports Strong Weight Loss Results For Dual-Acting Oral Drug
11 Sep 2024 //
FIERCE BIOTECH
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.